

Your patient's health plan may require a PA for Natevba<sup>®</sup>. This checklist can help to organize specific information about your patient's diagnosis and treatment history to complete a Natevba<sup>®</sup> PA.

**NOTE:** Prior authorization criteria and requirements may vary by health plan. Please be sure to verify the PA criteria and documentation required by your patient's insurer.

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Date of Service: \_\_\_\_\_  
 Physician: \_\_\_\_\_ PCP \_\_\_\_\_ Oncologist \_\_\_\_\_ Hematologist \_\_\_\_\_  
 Insurance Plan: \_\_\_\_\_ Plan Details: \_\_\_\_\_

## 1 DIAGNOSIS

### Examples of NHL Diagnosis Codes (including CLL)

C85.0	AIDS-related B-cell lymphoma	C82.9	Follicular lymphoma (FL)
C83.7	Burkitt lymphoma	C91.4	Hairy cell leukemia
D47.Z	Castleman's disease	C83.0	Low- or high-grade B-cell lymphoma
C91.1	Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)	C88.4	MALT lymphoma (gastric or nongastric)
C83.3	Diffuse large B-cell lymphoma (DLBCL)	C83.1	Mantle cell lymphoma

\*The sample diagnosis codes are informational only and not intended to be directive or a guarantee of reimbursement or coverage. This list includes FDA-approved indications for Natevba<sup>®</sup>. For a full list of ICD-10 codes, please consult the latest version of the ICD-10.

## 2 DOSE

Natevba<sup>®</sup> 5 mg/mL

Natevba<sup>®</sup> 10 mg/mL

## 3 MEDICAL HISTORY

Previous prescription therapies, treatment, chemotherapy or other relevant medical history. Include date and duration of treatment, reason for discontinuation (if applicable) and associated contraindications.

Request for Stage IV or metastatic cancer or associated symptoms

Patient has received at least one full dose of Natevba<sup>®</sup>



### INDICATION

Natevba<sup>®</sup> (vevasumab) is an antibody-drug conjugate indicated for the first-line treatment of adult patients with X-antigen-positive (XA+) non-Hodgkin's lymphoma (NHL).

### IMPORTANT SAFETY INFORMATION

Most common adverse reactions in clinical trials were: injection-site related pain or swelling, nausea, vomiting, abdominal pain, fatigue, infection and pyrexia. Please see full Prescribing Information and Important Safety Information at [www.natevba.com](http://www.natevba.com).